Abstract
Improved recognition of the relationship between childhood and adult blood pressures and identification of end-organ damage in children, adolescents, and young adults with hypertension has led to increased focus by pediatricians and general practitioners on the detection, evaluation, and treatment of hypertension. Notably, detection, evaluation, and treatment of pediatric hypertension has increased significantly since the first Task Force Report on High Blood Pressure in Children and Adolescents in 1977 with advances in both nonpharmacologic and pharmacologic treatments.
Angiotensin-converting enzyme inhibitors (e.g. captopril, enalapril, lisinopril, ramipril) and calcium channel antagonists (e.g. nifedipine, amlodipine, felodipine, isradipine) are the most commonly prescribed antihypertensive medications in children due to their low adverse-effect profiles. Diuretics (e.g. thiazide diuretics, loop diuretics, and potassium-sparing diuretics) are usually reserved as adjunct therapy. Newer agents, such as angiotensin receptor antagonists (e.g. irbesartan), are currently being studied in children and adolescents. These agents may be an option in children with chronic cough secondary to angiotensin-converting enzyme inhibitors. β-Adrenoreceptor antagonists (e.g. propranolol, atenolol, metoprolol, and labetalol), α-adrenoreceptor antagonists, α-adrenoreceptor agonists, direct vasodilators, peripheral adrenoreceptor neuron agonists, and combination products are less commonly used in pediatric patients because of adverse events but may be an option in children unresponsive to calcium channel blockers, angiotensin converting-enzyme inhibitors, or angiotensin receptor blockers.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157(21): 2413–46
Kannel WB. Role of blood pressure in cardiovascular disease: the Framingham Study. Angiology 1975; 26 (1 Pt 1): 1–14
Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001; 345(7): 479–86
Bao W, Threefoot SA, Srinivasan SR, et al. Essential hypertension predicted by tracking of elevated blood pressure from childhood to adulthood: the Bogalusa Heart Study. Am J Hypertens 1995; 8(7): 657–65
Beckett LA, Rosner B, Roche AF, et al. Serial changes in blood pressure from adolescence into adulthood. Am J Epidemiol 1992; 135(10): 1166–77
Lauer RM, Clarke WR. Childhood risk factors for high adult blood pressure: the Muscatine Study. Pediatrics 1989; 84(4): 633–41
Hashimoto N, Kawasaki T, Kikuchi T, et al. Criteria of normal blood pressure and hypertension in Japanese preschool children. J Hum Hypertens 1997; 11(6): 351–4
Kimm SY, Payne GH, Lakatos E, et al. Management of cardiovascular disease risk factors in children: a national survey of primary care physicians. Am J Dis Child 1990; 144(9): 967–72
Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Pediatrics 1996; 98 (4 Pt 1): 649–58
Report of the Second Task Force on Blood Pressure Control in Children: 1987. Task Force on Blood Pressure Control in Children. National Heart, Lung, and Blood Institute, Bethesda (MD). Pediatrics 1987; 79(1): 1–25
O’Sullivan J, Allen J, Murray A. A clinical study of the Korotkoff phases of blood pressure in children. J Hum Hypertens 2001; 15(3): 197–201
Hammond IW, Urbina EM, Wattigney WA, et al. Comparison of fourth and fifth Korotkoff diastolic blood pressures in 5 to 30 year old individuals: the Bogalusa Heart Study. Am J Hypertens 1995; 8(11): 1083–9
Canter DA, Texter MJ, McLain RW. Short report: ambulatory blood pressure monitoring can play an integral role in patient selection, dosage adjustment and efficacy assessment in clinical trials of antihypertensive agents. J Hypertens 1994; 12(4): 491–4
Canter DA, Texter MJ, McLain RW. Ambulatory blood pressure monitoring can play an integral role in patient selection, dosage adjustment and efficacy assessment in clinical trials of antihypertensive agents. J Hypertens Suppl 1994; 12(7): S33–8
Flynn JT. Impact of ambulatory blood pressure monitoring on the management of hypertension in children. Blood Press Monit 2000; 5(4): 211–6
Jacoby AC, Fixler DE, Torres EJ. Limitations of an oscillometric ambulatory blood pressure monitor in physically active children. J Pediatr 1993; 122(2): 231–6
Daniels SR, Loggie JM, Burton T, et al. Difficulties with ambulatory blood pressure monitoring in children and adolescents. J Pediatr 1987; 111(3): 397–400
Wilson PD, Ferencz C, Dischinger PC, et al. Twenty-four-hour ambulatory blood pressure in normotensive adolescent children of hypertensive and normotensive parents. Am J Epidemiol 1988; 127(5): 946–54
Portman RJ, Yetman RJ, West MS. Efficacy of 24-hour ambulatory blood pressure monitoring in children. J Pediatr 1991; 118(6): 842–9
Schwartz GL, Turner ST, Sing CF. Twenty-four-hour blood pressure profiles in normotensive sons of hypertensive parents. Hypertension 1992; 20(6): 834–40
Lurbe E, Redon J, Tacons J, et al. Current and birth weights exert independent influences on nocturnal pressure-natriuresis relationships in normotensive children. Hypertension 1998; 31 (1 Pt 2): 546–51
Lurbe E, Alvarez V, Liao Y, et al. The impact of obesity and body fat distribution on ambulatory blood pressure in children and adolescents. Am J Hypertens 1998; 11 (4 Pt 1): 418–24
Calzolari A, Giordano U, Matteucci MC, et al. Hypertension in young patients after renal transplantation: ambulatory blood pressure monitoring versus casual blood pressure. Am J Hypertens 1998; 11 (4 Pt 1): 497–501
Lip GY, Beevers M, Beevers DG, et al. The measurement of blood pressure and the detection of hypertension in children and adolescents. J Hum Hypertens 2001; 15(6): 419–23
de Man SA, Andre JL, Bachmann H, et al. Blood pressure in childhood: pooled findings of six European studies. J Hypertens 1991; 9(2): 109–14
Sinaiko AR. Hypertension in children. N Engl J Med 1996; 335(26): 1968–73
Court JM, Hill GJ, Dunlop M, et al. Hypertension in childhood obesity. Aust Paediatr J 1974; 10(5): 296–300
Schieken RM, Clarke WR, Lauer RM. Left ventricular hypertrophy in children with blood pressures in the upper quintile of the distribution: the Muscatine Study. Hypertension 1981; 3(6): 669–75
Zahka KG, Neill CA, Kidd L, et al. Cardiac involvement in adolescent hypertension: echocardiographic determination of myocardial hypertrophy. Hypertension 1981; 3(6): 664–8
Culpepper III WS, Sodt PC, Messerli FH, et al. Cardiac status in juvenile borderline hypertension. Ann Intern Med 1983; 98(1): 1–7
Daniels SD, Meyer RA, Loggie JM. Determinants of cardiac involvement in children and adolescents with essential hypertension. Circulation 1990; 82(4): 1243–8
Killeen J, Vanderburg D, Harlan WR. Application of weight-height ratios and body indices to juvenile populations: the National Health Examination Survey Data. J Chronic Dis 1978; 31(8): 529–37
Cook NR, Gillman MW, Rosner BA, et al. Prediction of young adult blood pressure from childhood blood pressure, height, and weight. J Clin Epidemiol 1997; 50(5): 571–9
Rocchini AP, Katch V, Anderson J, et al. Blood pressure in obese adolescents: effect of weight loss. Pediatrics 1988; 82(1): 16–23
Rocchini AP, Key J, Bondie D, et al. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med 1989; 321(9): 580–5
Fletcher GF, Balady G, Blair SN, et al. Statement on exercise: benefits and recommendations for physical activity programs for all Americans. A statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart Association. Circulation 1996; 94(4): 857–62
Washington RL, Bricker JT, Alpert BS, et al. Guidelines for exercise testing in the pediatric age group: from the Committee on Atherosclerosis and Hypertension in Children, Council on Cardiovascular Disease in the Young, the American Heart Association. Circulation 1994; 90(4): 2166–79
Shea S, Basch CE, Gutin B, et al. The rate of increase in blood pressure in children 5 years of age is related to changes in aerobic fitness and body mass index. Pediatrics 1994; 94 (4 Pt 1): 465–70
Fagard R, Bielen E, Lijnen P, et al. Cardiac variables and blood pressure as determinants of left ventricular inflow velocities. J Hum Hypertens 1993; 7(1): 7–12
Johnson RJ, Schreiner GF. Hypothesis: the role of acquired tubulointerstitial disease in the pathogenesis of salt-dependent hypertension. Kidney Int 1997; 52(5): 1169–79
Howe PR, Cobiac L, Smith RM. Lack of effect of short-term changes in sodium intake on blood pressure in adolescent schoolchildren. J Hypertens 1991; 9(2): 181–6
Howe PR, Lungershausen YK, Rogers PF, et al. Effects of dietary sodium and fish oil on blood pressure development in stroke-prone spontaneously hypertensive rats. J Hypertens 1991; 9(7): 639–44
Falkner B, Michel S. Blood pressure response to sodium in children and adolescents. Am J Clin Nutr 1997; 65(2 Suppl.): 618S–21S
Crowther JH. Stress management training and relaxation imagery in the treatment of essential hypertension. J Behav Med 1983; 6(2): 169–87
Wells T, Frame V, Soffer B, et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol 2002; 42(8): 870–80
Soergel M, Verho M, Wuhl E, et al. Effect of ramipril on ambulatory blood pressure and albuminuria in renal hypertension. Pediatr Nephrol 2000; 15(1–2): 113–8
Khattak S, Rogan JW, Saunders EF, et al. Efficacy of amlodipine in pediatric bone marrow transplant patients. Clin Pediatr (Phila) 1998; 37(1): 31–5
Pfammatter JP, Clericetti-Affolter C, Truttmann AC, et al. Amlodipine once daily in systemic hypertension. Eur J Pediatr 1998; 157(8): 618–21
Falkner B, Lowenthal DT, Affrime MB. The pharmacodynamic effectiveness of metoprolol in adolescent hypertension. Pediatr Pharmacol (New York) 1982; 2(1): 49–55
Sorof JM, Cargo P, Graepel J, et al. Beta-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial. Pediatr Nephrol 2002; 17(5): 345–50
Flynn JT, Pasko DA. Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension. Pediatr Nephrol 2000; 15(3–4): 302–16
Krolewski AS, Canessa M, Warram JH, et al. Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. N Engl J Med 1988; 318(3): 140–5
Doyle AE. Role of angiotensin-converting enzyme inhibitors in preventing or reducing end-organ damage in hypertension. J Cardiovasc Pharmacol 1992; 19Suppl. 5: S21–7
Freis ED, Papademetriou V. Current drug treatment and treatment patterns with antihypertensive drugs. Drugs 1996; 52(1): 1–16
Laffel LM, McGill JB, Gans DJ. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria: North American Microalbuminuria Study Group. Am J Med 1995; 99(5): 497–504
National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension 1994; 23(2): 145–58
Tack ED, Perlman JM. Renal failure in sick hypertensive premature infants receiving captopril therapy. J Pediatr 1988; 112(5): 805–10
Mirkin BL, Newman TJ. Efficacy and safety of captopril in the treatment of severe childhood hypertension: report of the International Collaborative Study Group. Pediatrics 1985; 75(6): 1091–100
O’Dea RF, Mirkin BL, Alward CT, et al. Treatment of neonatal hypertension with captopril. J Pediatr 1988; 113(2): 403–6
Sinaiko AR, Kashtan CE, Mirkin BL. Antihypertensive drug therapy with captopril in children and adolescents. Clin Exp Hypertens A 1986; 8(4–5): 829–39
Sinaiko AR, Mirkin BL, Hendrick DA, et al. Antihypertensive effect and elimination kinetics of captopril in hypertensive children with renal disease. J Pediatr 1983; 103(5): 799–805
Morsi MR, Madina EH, Anglo AA, et al. Evaluation of captopril versus reserpine and frusemide in treating hypertensive children with acute post-streptococcal glomerulonephritis. Acta Paediatr 1992; 81(2): 145–9
Callis L, Vila A, Catala J, et al. Long-term treatment with captopril in pediatric patients with severe hypertension and chronic renal failure. Clin Exp Hypertens A 1986; 8(4–5): 847–51
Rosendahl W, Hayduk K. Successful acute and long-term treatment of renin-induced hypertension in two infants with captopril. Eur J Pediatr 1980; 135(2): 161–4
Schneeweiss A. Cardiovascular drugs in children: II. Angiotensin-converting enzyme inhibitors in pediatric patients. Pediatr Cardiol 1990; 11(4): 199–207
Prasher PK, Varma PP, Baliga KV. Efficacy of enalapril in the treatment of steroid resistant idiopathic nephrotic syndrome. J Assoc Physicians India 1999; 47(2): 180–2
Miller K, Atkin B, Rodel Jr PV, et al. Enalapril: a well-tolerated and efficacious agent for the pediatric hypertensive patient. J Cardiovasc Pharmacol 1987; 10Suppl. 7: S154–6
Wells T, Rippley R, Hogg R, et al. The pharmacokinetics of enalapril in children and infants with hypertension. J Clin Pharmacol 2001; 41(10): 1064–74
Rippley RK, Connor J, Boyle J, et al. Pharmacokinetic assessment of an oral enalapril suspension for use in children. Biopharm Drug Dispos 2000; 21(9): 339–44
Schilder JL, Van den Anker JN. Use of enalapril in neonatal hypertension. Acta Paediatr 1995; 84(12): 1426–8
Herrera P, Soffer B, Zhang Z, et al. Effects of the ACE inhibitor, lisinopril in children age 6–16 years [abstract]. Am J Hypertens 2002; 15(4): 32A
Shaw W, Hogg R, Delucchi A, et al. Lisinopril pharmacokinetics in hypertensive children and infants [abstract]. Am J Hypertens 2002; 15(4): 46A
Shaw W, Hogg R, Delucchi A, et al. Multicenter study of lisinopril pharmacokinetics (PK) in hypertensive children and infants [abstract]. Pediatr Res 2002; 51(4): 431A
Bouissou F, Meguira B, Rostin M, et al. Long term therapy by captopril in children with renal hypertension. Clin Exp Hypertens A 1986; 8(4–5): 841–5
Oberfield SE, Rapaport R, Levine LS, et al. Long-term treatment of childhood hypertension with captopril. Pediatr Ann 1982; 11(7): 614–6, 620-1
Chan MK, Sweny P, El Nahas AM, et al. Captopril in hypertension after renal transplantation. Postgrad Med J 1984; 60(700): 132–4
Hymes LC, Warshaw BL. Captopril: long-term treatment of hypertension in a preterm infant and in older children. Am J Dis Child 1983; 137(3): 263–6
Andreucci VE, Conte G, Dal Canton A, et al. The causal role of salt depletion in acute renal failure due to captopril in hypertensive patients with a single functioning kidney and renal artery stenosis. Ren Fail 1987; 10(1): 9–20
Hiyarat AM. Case history: treatment of bilateral renovascular hypertension in an 8-year-old child with captopril-ACE inhibitor. J Int Med Res 1982; 10(6): 451–4
Lip GY, Churchill D, Beevers M, et al. Angiotensin-converting-enzyme inhibitors in early pregnancy. Lancet 1997; 350(9089): 1446–7
Pryde PG, Sedman AB, Nugent CE, et al. Angiotensin-converting enzyme inhibitor fetopathy. J Am Soc Nephrol 1993; 3(9): 1575–82
Perlman JM, Volpe JJ. Neurologic complications of captopril treatment of neonatal hypertension. Pediatrics 1989; 83(1): 47–52
Fassett RG, Walker RG, Whitworth JA, et al. Repeated renal failure with captopril [letter]. BMJ (Clin Res Ed) 1983; 286(6365): 648
Sakarcan A, Tenney F, Wilson JT, et al. The pharmacokinetics of irbesartan in hypertensive children and adolescents. J Clin Pharmacol 2001; 41(7): 742–9
Fernandez-Andrade C, Russo D, Iversen B, et al. Comparison of losartan and amlodipine in renally impaired hypertensive patients. Kidney Int Suppl 1998; 68: S120–4
Singh BN. The mechanism of action of calcium antagonists relative to their clinical applications. Br J Clin Pharmacol 1986; 21Suppl. 2: 109S–21S
Jung FF, Ingelfinger JR. Hypertension in childhood and adolescence. Pediatr Rev 1993; 14(5): 169–79
Sinaiko AR. Clinical pharmacology of converting enzyme inhibitors, calcium channel blockers and diuretics. J Hum Hypertens 1994; 8(5): 389–94
Luft FC, Miller JZ, Lyle RM, et al. The effect of dietary interventions to reduce blood pressure in normal humans. J Am Coll Nutr 1989; 8(6): 495–503
Luft FC. Salt and hypertension: recent advances and perspectives. J Lab Clin Med 1989; 114(3): 215–21
White WB, Viadero JJ, Lane TJ, et al. Effects of combination therapy with captopril and nifedipine in severe or resistant hypertension. Clin Pharmacol Ther 1986; 39(1): 43–8
Luke RG. Pathophysiology and treatment of post-transplant hypertension. J Am Soc Nephrol 1991; 2 (2 Suppl. 1): S37–44
Rowland TW. The pediatrician and congenital heart disease: 1979. Pediatrics 1979; 64(2): 180–6
Piovan D, Padrini R, Svalato Moreolo G, et al. Verapamil and norverapamil plasma levels in infants and children during chronic oral treatment. Ther Drug Monit 1995; 17(1): 60–7
Johnson CE, Jacobson PA, Song MH. Isradipine therapy in hypertensive pediatric patients. Ann Pharmacother 1997; 31(6): 704–7
Flynn JT, Warnick SJ. Isradipine treatment of hypertension in children: a singlecenter experience. Pediatr Nephrol 2002; 17(9): 748–53
Johnson BF, Eisner GM, McMahon FG, et al. A multicenter comparison of adverse reaction profiles of isradipine and enalapril at equipotent doses in patients with essential hypertension. J Clin Pharmacol 1995; 35(5): 484–92
Ahmed K, Michael B, Burke Jr JF. Effects of isradipine on renal hemodynamics in renal transplant patients treated with cyclosporine. Clin Nephrol 1997; 48(5): 307–10
Strauser LM, Groshong T, Tobias JD. Initial experience with isradipine for the treatment of hypertension in children. South Med J 2000; 93(3): 287–93
Roth B, Herkenrath P, Krebber J, et al. Nifedipine in hypertensive crises of infants and children. Clin Exp Hypertens A 1986; 8(4–5): 871–7
Dilmen U, Caglar MK, Senses DA, et al. Nifedipine in hypertensive emergencies of children. Am J Dis Child 1983; 137(12): 1162–5
Foster TS, Hamann SR, Richards VR, et al. Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects. J Clin Pharmacol 1983; 23(4): 161–70
Moncica I, Oh PI, ul Qamar I, et al. A crossover comparison of extended release felodipine with prolonged action nifedipine in hypertension. Arch Dis Child 1995; 73(2): 154–6
Silverstein DM, Palmer J, Baluarte HJ, et al. Use of calcium-channel blockers in pediatric renal transplant recipients. Pediatr Transplant 1999; 3(4): 288–92
Wells TG, Sinaiko AR. Antihypertensive effect and pharmacokinetics of nitrendipine in children. J Pediatr 1991; 118 (4 Pt 1): 638–43
Martin A, Cuevas B, Escudero E, et al. Antiproteinuric effect of calcium antagonists on puromycin-induced experimental nephrosis. Ren Fail 2000; 22(1): 17–26
Flynn JT, Smoyer WE, Bunchman TE. Treatment of hypertensive children with amlodipine. Am J Hypertens 2000; 13(10): 1061–6
Tallian KB, Nahata MC, Turman MA, et al. Efficacy of amlodipine in pediatric patients with hypertension. Pediatr Nephrol 1999; 13(4): 304–10
Flynn JT, Ludden T, Mahan JD. Population pharmacokinetics of amlodipine in children with hypertension [abstract]. Am J Hypertens 2002; 15(4): 206A
Flynn JT, Hogg R, Portman RJ. A randomized, placebo controlled trial of amlodipine in the treatment of children with hypertension [abstract]. Am J Hypertens 2002; 15(4): 31A
Parker ML, Robinson RF, Nahata MC. Amlodipine therapy in pediatric patients with hypertension. J Am Pharm Assoc (Wash) 2002; 42(1): 114–7
Rogan JW, Lyszkiewicz DA, Blowey D, et al. A randomized prospective crossover trial of amlodipine in pediatric hypertension. Pediatr Nephrol 2000; 14(12): 1083–7
Abernethy DR. The pharmacokinetic profile of amlodipine. Am Heart J 1989; 118 (5 Pt 2): 1100–3
von Vigier RO, Franscini LMD, Bianda NDF. Antihypertensive efficacy of amlodipine in children with chronic kidney diseases. J Hum Hypertens 2001; 15: 387–91
Nahata MC, Morosco RS, Hipple TF. Stability of amlodipine besylate in two liquid dosage forms. J Am Pharm Assoc (Wash) 1999; 39(3): 375–7
Blowey DI, Moncica I, Scolnik D, et al. The pharmacokinetics of extended release felodipine in children. Eur J Clin Pharmacol 1996; 50(1–2): 147–8
Endresen L, Bergan S, Holdaas H, et al. Lack of effect of the calcium antagonist isradipine on cyclosporine pharmacokinetics in renal transplant patients. Ther Drug Monit 1991; 13(6): 490–5
MacDonald JL, Johnson CE, Jacobson P. Stability of isradipine in an extemporaneously compounded oral liquid. Am J Hosp Pharm 1994; 51(19): 2409–11
Gavras I, Gavras H, Sullivan PC, et al. A comparative study of the effects of oxprenolol versus propranolol in essential hypertension. J Clin Pharmacol 1979; 19(1): 8–14
Kornbluth A, Frishman WH, Ackerman M. Beta-adrenergic blockade in children. Cardiol Clin 1987; 5(4): 629–49
Griswold WR, McNeal R, Mendoza SA, et al. Propranolol as an antihypertensive agent in children. Arch Dis Child 1978; 53(7): 594–6
Friedman AL, Hustead VA. Hypertension in babies following discharge from a neonatal intensive care unit: a 3-year follow-up. Pediatr Nephrol 1987; 1(1): 30–4
Webster J, Petrie JC, Robb OJ, et al. Enalapril in moderate to severe hypertension: a comparison with atenolol. Br J Clin Pharmacol 1986; 21(5): 489–95
Frishman WH, Brobyn R, Brown RD, et al. A randomized placebo-controlled comparison of amlodipine and atenolol in mild to moderate systemic hypertension. J Cardiovasc Pharmacol 1988; 12Suppl. 7: S103–6
Rofman BA. Long-term open evaluation of amlodipine versus hydrochlorothiazide in patients with essential hypertension. J Cardiovasc Pharmacol 1988; 12Suppl. 7: S94–7
Ishisaka DY, Yonan CD, Housel BF. Labetalol for treatment of hypertension in a child. Clin Pharm 1991; 10(7): 500–1
Bunchman TE, Lynch RE, Wood EG. Intravenously administered labetalol for treatment of hypertension in children. J Pediatr 1992; 120(1): 140–4
Beermann B, Groschinsky-Grind M, Rosen A. Absorption, metabolism, and excretion of hydrochlorothiazide. Clin Pharmacol Ther 1976; 19 (5 Pt 1): 531–7
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265(24): 3255–64
Sadowski RH, Falkner B. Hypertension in pediatric patients. Am J Kidney Dis 1996; 27(3): 305–15
Peterson RG, Simmons MA, Rumack BH, et al. Pharmacology of furosemide in the premature newborn infant. J Pediatr 1980; 97(1): 139–43
Tuck S, Morselli P, Broquaire M, et al. Plasma and urinary kinetics of furosemide in newborn infants. J Pediatr 1983; 103(3): 481–5
Aranda JV, Lambert C, Perez J, et al. Metabolism and renal elimination of furosemide in the newborn infant. J Pediatr 1982; 101(5): 777–81
Mirochnick MH, Miceli JJ, Kramer PA, et al. Furosemide pharmacokinetics in very low birth weight infants. J Pediatr 1988; 112(4): 653–7
Hess HJ. Prazosin: biochemistry and structure-activity studies. Postgrad Med 1975; Spec No: 9–17
Stokes GS. Age-related effects of antihypertensive therapy with alpha-blockers. J Cardiovasc Pharmacol 1988; 12Suppl. 8: S109–15
Stanaszek WF, Kellerman D, Brogden RN, et al. Prazosin update: a review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure. Drugs 1983; 25(4): 339–84
Talseth T. Clinical pharmacokinetics of hydralazine. Clin Pharmacokinet 1977; 2(5): 317–29
Talseth T. Kinetics of hydralazine elimination. Clin Pharmacol Ther 1977; 21(6): 715–20
Cifkova R, Nakov R, Novozamska E, et al. Evaluation of the effects of fixed combinations of sustained-release verapamil/trandolapril versus captopril/hydrochlorothiazide on metabolic and electrolyte parameters in patients with essential hypertension. J Hum Hypertens 2000; 14(6): 347–54
Luccioni R, Sever PS, Di Perri T, et al. An equivalence study of the safety and efficacy of a fixed-dose combination of perindopril with indapamide versus fixed-dose combinations of captopril with hydrochlorothiazide and enalapril with hydrochlorothiazide in the treatment of hypertension. J Hypertens 1995; 13 (12 Pt 2): 1847–51
Acknowledgments
No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Robinson, R.F., Nahata, M.C., Batisky, D.L. et al. Pharmacologic Treatment of Chronic Pediatric Hypertension. Pediatr-Drugs 7, 27–40 (2005). https://doi.org/10.2165/00148581-200507010-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00148581-200507010-00003